Neue Fund

Total investments

55

Average round size

2M

Portfolio companies

40

Rounds per year

11.00

Follow on index

0.24

Exits

1

Areas of investment
BiotechnologySoftwareInformation TechnologyArtificial IntelligenceMachine LearningHealth CareMedical DeviceMedicalLife ScienceAgTech

Investments analytics

Analytics

Total investments
55
Lead investments
0
Exits
1
Rounds per year
11.00
Follow on index
0.24
Investments by industry
  • Biotechnology (21)
  • Health Care (18)
  • Medical Device (9)
  • Software (9)
  • Artificial Intelligence (8)
  • Show 48 more
Investments by region
  • United States (44)
  • China (2)
  • Colombia (1)
  • Germany (1)
  • United Kingdom (1)
  • Show 2 more
Peak activity year
2020

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
6
Avg. valuation at time of investment
27M
Group Appearance index
0.31
Avg. company exit year
7

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Clean Energy Global 15 Aug 2018 Energy, Clean Energy, Battery Seed 206K Berlin, Germany
Insilico Medicine 09 Sep 2019 Biotechnology, Artificial Intelligence, Health Care, Genetics, Pharmaceutical Early Stage Venture 37M Hong Kong Island, Hong Kong, China
SentiAR 31 Mar 2020 Biotechnology, Software, Health Care, 3D Technology, Medical Device, Augmented Reality Early Stage Venture United States, Missouri, City of Saint Louis
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.